About us

Welcome to the website of Dr Hanns Lochmüller’s research group in Ottawa, Canada. These pages are maintained by group members to provide an overview of our research and clinical activities.

We focus on scientific, genetic and clinical research into rare neuromuscular disorders and clinical care for patients with these conditions. We aim to understand why small variations in the human genome lead to these frequently disabling, sometimes lethal, and rarely treatable conditions affecting the musculature and nervous system. Our group has a bench-to-bedside translational approach, from identifying underlying genetic defects in patients using deep phenotyping and next-generation sequencing, through unravelling molecular pathways in cell and animal models, to testing new targeted therapies in clinical trials.

Hanns is affiliated with the CHEO Research Institute’s Molecular Biomedicine Program and the CHEO Department of Pediatrics, as well as  the Department of Medicine, Division of Neurology of The Ottawa Hospital and the Department of Cellular and Molecular Medicine and the Brain and Mind Research Institute at the University of Ottawa. His group members work across various of these affiliations and he has close collaborations with many other research groups across the world.

 

 

 

*Photo © Team Hanns in Newcastle, UK – many of whom still collaborate closely with Hanns in his new role

Hanns's research team in Newcastle, UK

Read next...

Map of Ottawa showing CHEO-RI location

Contact us

Contact us Mailing address: CHEO Research Institute 401 Smyth Road Ottawa, ON K1H 8L1 Canada   Email addresses: See the…

Collaborations

Our research is founded on strong collaborations with leading investigators, academic groups, patient organizations and industrial partners within Canada and worldwide. Prior to moving to Canada, Hanns was based in Europe (Germany and UK) and has maintained the strong international collaborations he has developed throughout his career.

Image of the Ottawa Hospital Civic Campus

Clinical work

Hanns sees neuromuscular patients in clinic at the Neuromuscular Research Centre, located at the Civic Campus of The Ottawa Hospital. This newly opened state-of-the-art centre allows people with NMDs to have consultations with neuromuscular experts and to participate in clinical research.

Rack of newspapers

News

Read the latest news about our group, our research, our collaborations and our publications here. You can also follow us on Twitter – search for @LochmullerLab.

medicine capsules spilling out of a jar

Industry collaborations

Collaboration with the pharmaceutical industry is essential in order to achieve the translation of preclinical research findings into clinical trials. Hanns is an experienced investigator in commercially sponsored clinical studies and our group also works closely with basic research teams within pharma companies on various preclinical studies.

Publications

You can find our most recent publications here – both those coming out of the Lochmüller lab directly and those…

Diseases of interest

Our group is interested in rare inherited neuromuscular diseases, in particular congenital myasthenic syndromes, myotonic dystrophy, GNE myopathy, Duchenne muscular dystrophy and spinal muscular atrophy. We investigate these conditions in the lab and in the clinic in a “bench to bedside” approach.

Researcher using a pipette in a fume hood

Research areas

Although individually uncommon, rare diseases are so numerous that they collectively affect as many as one person in every 17 – in Canada, about 2 million people. Our research program focuses on defining the basic molecular and cellular mechanisms that cause neuromuscular disorders, to enable improved diagnosis, better care and development of effective treatments.

The Lochmuller Lab team

Team members

Find out more about Hanns and his team members here and see whether you would like to join us! We are always interested in hearing from scientists and clinicians at all stages of their careers, whether you want to join the team or start a scientific collaboration.